Effectiveness of very low doses of immunotherapy in advanced renal cell cancer
C Buzio, G De Palma, R Passalacqua, D Potenzoni, F Ferrozzi, M A Cattabiani, L Manenti, A Borghetti, C Buzio, G De Palma, R Passalacqua, D Potenzoni, F Ferrozzi, M A Cattabiani, L Manenti, A Borghetti
Abstract
Twenty-one nephrectomized patients with metastatic renal cell cancer were treated with recombinant interleukin 2 (rlL-2) and interferon alpha (rIFN alpha). rIL-2 was administered s.c. at a dose of 1 x 10(6) IU m(-2) every 12 h on days 1 and 2, followed by 0.5 x 10(6) IU twice daily on days 3-5; rIFN alpha-2 was given i.m. as 1.8 x 10(6) IU m(-2) on days 3 and 5 of each week for 4 consecutive weeks. The cycle was regularly repeated at 4-month intervals and continued ad libitum in patients showing some response and in patients with progressing disease. Of 20 patients evaluable for treatment response, one (5%) had a complete response and three (15%) showed partial response. Three patients (15%) achieved stable disease and 13 (65%) were evaluated as having progressive disease. The estimated actuarial 44-month survival rate was 44%. Toxicity was limited to WHO grades 1 and 2 only.
References
- Semin Oncol. 1993 Dec;20(6 Suppl 9):3-10
- Br J Cancer. 1993 Sep;68(3):559-67
- Tumori. 1993 Dec 31;79(6):397-400
- Eur J Cancer. 1994;30A(4):530-2
- Eur J Cancer. 1994;30A(9):1310-4
- Cancer. 1970 Oct;26(4):780-7
- Cancer. 1981 Jan 1;47(1):207-14
- N Engl J Med. 1987 Apr 9;316(15):889-97
- N Engl J Med. 1987 Apr 9;316(15):898-905
- Cancer Res. 1988 May 1;48(9):2561-7
- J Clin Oncol. 1988 Sep;6(9):1440-9
- J Exp Med. 1990 May 1;171(5):1509-26
- Lancet. 1990 Jun 23;335(8704):1509-12
- Nature. 1991 Oct 31;353(6347):858-61
- Semin Oncol. 1991 Oct;18(5 Suppl 7):108-12
- Ann Oncol. 1992 Jun;3(6):475-80
- Acta Haematol. 1993;89(1):13-21
- JAMA. 1994 Mar 23-30;271(12):907-13
Source: PubMed